miR-203 promotes HaCaT cell overproliferation through targeting LXR-α and PPAR-γ

References

• Beek CH, van Reede EC. The nature and frequency of the histological changes found in psoriasis vulgaris. Arch Dermatol Res. 1977;257(3):255–264.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin Y, Li C, et al. IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis. J Immunol. 2016;197(6):2131–2144.
   PubMed Web of Science ®Google Scholar
• Teng X, Hu Z, Wei X, et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol. 2014;192(4):1815–1823.
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014–1022.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Pallone F, MacDonald T, et al. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond). 2011;120(1):1–11.
   PubMed Web of Science ®Google Scholar
• Cabrijan L, Lipozenčić J, Batinac T, et al. Psoriasis vulgaris - an inflammatory skin disease and/or benign epidermal hyperplasia. Acta Dermatovenerol Croat. 2011;19(2):117–119.
   PubMed Web of Science ®Google Scholar
• Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385–422.
   PubMed Web of Science ®Google Scholar
• Asadullah K, Döcke WD, Volk HD, et al. The pathophysiological role of cytokines in psoriasis. Drugs Today (Barc). 1999;35(12):913–924.
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450–456.
   PubMed Web of Science ®Google Scholar
• Stuart P, Malick F, Nair RP, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002;294(5):207–213.
   PubMed Web of Science ®Google Scholar
• Gupta DS, Kaul D, Kanwar AJ, et al. Psoriasis: crucial role of LXR-alpha RNomics. Genes Immun. 2010;11(1):37–44.
   PubMed Web of Science ®Google Scholar
• Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9(3):219–230.
   PubMed Web of Science ®Google Scholar
• Zibert JR, Løvendorf MB, Litman T, et al. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci. 2010;58(3):177–185.
   PubMed Web of Science ®Google Scholar
• Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60(16):1340–1355.
   PubMed Web of Science ®Google Scholar
• Han D, Kim H-Y, Lee H-J, et al. Wound healing activity of gamma-aminobutyric Acid (GABA) in rats. J Microbiol Biotechnol. 2007;17(10):1661–1669.
   PubMed Web of Science ®Google Scholar
• Liu H, Deng H, Zhao Y, et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 2018;37(1):279.
   PubMedGoogle Scholar
• Liu Z, Dou C, Yao B, et al. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget. 2016;7(18):25350–25365.
   PubMedGoogle Scholar
• Tu K, LIU Z, YAO B, et al. MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol. 2016;48(3):965–974.
   PubMed Web of Science ®Google Scholar
• Donato L, Scimone C, Rinaldi C, et al. Stargardt phenotype associated with two ELOVL4 promoter variants and ELOVL4 downregulation: new possible perspective to etiopathogenesis? Invest Ophthalmol Vis Sci. 2018;59(2):843–857.
   PubMed Web of Science ®Google Scholar
• Joyce CE, Zhou X, Xia J, et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet. 2011;20(20):4025–4040Xu Y, Ji Y, Lan X, et al. miR‑203 contributes to IL‑17‑induced VEGF secretion by targeting SOCS3 in keratinocytes[J]. Mol Med Rep. 2017;16(6):8989..
   PubMed Web of Science ®Google Scholar
• XU Y, Ji Y, Lan X, et al. miR‑203 contributes to IL‑17‑induced VEGF secretion by targeting SOCS3 in keratinocytes[J]. Mol Med Rep. 2017;16(6):8989.
   Google Scholar
• Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun. 2007;8(1):1–12.
   PubMed Web of Science ®Google Scholar
• Sabat R, Philipp S, Höflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16(10):779–798.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17(6):985–993.
   PubMedGoogle Scholar
• Hanley K, Ng DC, He S, et al. Oxysterols induce differentiation in human keratinocytes and increase Ap-1-dependent involucrin transcription. J Invest Dermatol. 2000;114(3):545–553.
   PubMed Web of Science ®Google Scholar
• Komuves LG, Schmuth M, Fowler AJ, et al. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Invest Dermatol. 2002;118(1):25–34.
   PubMed Web of Science ®Google Scholar
• Schmuth M, Elias PM, Hanley K, et al. The effect of LXR activators on AP-1 proteins in keratinocytes. J Invest Dermatol. 2004;123(1):41–48.
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–322.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yin M, Zhang LJ. Keratin 6, 16 and 17-critical barrier alarmin molecules in skin wounds and psoriasis. Cells. 2019;8(8):807.
   Web of Science ®Google Scholar
• Sonkoly E, Wei T, Janson PCJ, et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2007;2(7):e610.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Nguyen GH, Fujita M, et al. microRNAs in psoriasis. J Invest Dermatol. 2016;136(2):365–371.
   PubMed Web of Science ®Google Scholar
• Raaby L, Langkilde A, Kjellerup RB, et al. Changes in mRNA expression precede changes in micro RNA expression in lesional psoriatic skin during treatment with adalimumab. Br J Dermatol. 2015;173(2):436–447.
   PubMed Web of Science ®Google Scholar
• Lerman G, Avivi C, Mardoukh C, et al. MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One. 2011;6(6):e20916.
   PubMed Web of Science ®Google Scholar
• Wang M-J, Xu -Y-Y, Huang R-Y, et al. Role of an imbalanced miRNAs axis in pathogenesis of psoriasis: novel perspectives based on review of the literature. Oncotarget. 2017;8(3):5498–5507.
   PubMedGoogle Scholar
• Sonkoly E, Wei T, Pavez Loriè E, et al. Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol. 2010;130(1):124–134.
   PubMed Web of Science ®Google Scholar
• Donato L, Scimone C, Nicocia G, et al. Role of oxidative stress in Retinitis pigmentosa: new involved pathways by an RNA-Seq analysis. Cell Cycle. 2019;18(1):84–104.
   PubMed Web of Science ®Google Scholar
• Donato L, Scimone C, Rinaldi C, et al. Non-coding RNAome of RPE cells under oxidative stress suggests unknown regulative aspects of retinitis pigmentosa etiopathogenesis. Sci Rep. 2018;8(1):16638.
   PubMedGoogle Scholar
• Rinaldi C, Bramanti P, Famà A, et al. Glyoxalase I A111e, paraoxonase 1 Q192r and L55m polymorphisms in Italian patients with sporadic cerebral cavernous malformations: a pilot study. J Biol Regul Homeost Agents. 2015;29(2):493–500.
   PubMed Web of Science ®Google Scholar
• Donato L, Scimone C, Nicocia G, et al. GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population. Mol Biol Rep. 2018;45(5):1349–1355.
   PubMed Web of Science ®Google Scholar